Skip to main content
  • Policy
    Get Involved
    Join BIOAction
    View Advocacy Toolkit
    Patient Advocacy
    Human Health
    Cost and Value of Biopharmaceuticals
    Antimicrobial Resistance
    Vaccines & Biodefense
    Drug Development & Review
    International
    Global Markets & Trade
    Multilateral Organizations
    Intellectual Property
    All Policy
    Patient Advocacy

    Join BIO as we champion for bringing new treatments to patients with serious medical conditions and to support policies that promote innovation and improve patient access.

  • Member
    Membership Options
    Become a BIO Member
    Member Directory
    Have a Voice
    Membership Eligibility
    Member Toolkit
    Benefits By Sector
    member health
    Human Health
    member startups
    Startups
    member non R&D
    Non-R&D Companies
    Member Savings
    BBS-Programs-vwr
    VWR, Part of Avantor
    75% off Lab Supplies
    Save with BIO
    Save with BIO
  • News & Insights
    Latest biotech news
    Popular blogs
    Events
    Policy
    BIO Statements
    Press Releases
    Letters, Testimony & Comments
    Amicus Briefs
    BIO Reports
    Industry Analysis Reports
    Biotech Jobs
    Economic Development Best Practices
    BIO Briefly
    Issue Briefs
    BIO.News
    I am BIO Podcast
    All News & Insights

    Sign up for the BIO.News Newsletter >

  • Events
    Event Portfolio
    Business Development
    Health
    International
    Professional Development
    Members Only
    All Events
    BIO International Convention

    June 22-25, 2026 | San Diego, CA

    Learn More
    BIO Asia-Taiwan
    BIO Europe

    November 3-5, 2025
    Vienna, Austria

    BIO Investor Forum
    Partnering @JPM Week

    January 12-15, 2026
    San Francisco, CA

    BIO Patient & Health Advocacy Summit
    BIO Investment & Growth Summit

    March 2-3, 2026
    Miami, FL

    BIO Webinars

    Explore the webinar opportunities for interactive, online learning about emerging issues in biotechnology public policy, scientific progress, and raising capital, plus methods to benefit from BIO’s membership services.

  • About
    About Us
    Learn about our priorities
    BIO Leadership
    Meet BIO's Senior Leadership and Board of Directors
    Biotech Basics
    Read about biotechnology
    Industry Recognition
    Get to know the outstanding people and companies BIO supports
    Careers @ BIO
    Explore job openings with BIO today
    Diversity & Inclusion >

    Our tools and initiatives on workforce development, diversity and inclusion are designed to advance a more globally competitive industry.

  • Resource Hub
    Latest Resources
    BIO Early-Stage Resources Hub
    BIO Professional Development
    BIO Content Hub
    Biotech News (BIO.News)
    BIO.News Newsletter
    I am BIO Podcast
    BIO Advocacy Toolkit
    Resources Hub
    BIO Early-Stage Resources Hub
    BIO Professional Development
    BIO Webinars
    BIO Microsites
    Clinical Trials: The Power of Participation
    Covid Vaccine Facts
  • Search Results
    Previously Searched
Logo
Logo
Home
Search
  • Policy
    Human HealthPatient AdvocacyInternationalIntellectual PropertyAll Policies
  • Member
    Become a BIO MemberBenefits By Sector
    Human HealthStartupsNon-R&D Companies
    Member DirectoryHave a VoiceMembership EligibilitySavings
  • News & Insights
    Press ReleasesBio.News BlogLetters, Testimony & CommentsAmicus BriefsIndustry Analysis ReportsBiotech JobsEconomic Development Best PracticesIssue BriefsBIO.NewsVideosAll News & Insights
  • Events
    BIO International ConventionBIO Asia-TaiwanAll Events
  • About
    About UsBIO LeadershipDiversity & InclusionBiotech BasicsIndustry RecognitionCareers @ BIO
  • Resource Hub
    Biotech News (BIO.News)BIO.News NewsletterI am BIO PodcastBIO Advocacy ToolkitBIO Early-Stage Resources HubBIO Professional DevelopmentBIO WebinarsClinical Trials: The Power of ParticipationCovid Vaccine Facts
Search Results
Previously Searched
Search Results
Previously Searched
3145 results found
Expand All
Apply All
3145 results found

Year Round Engagement Opportunities
Share

Medicare's Alzheimer's announcement
Share
Good Day BIO Newsletter  •  June 2, 2023
Medicare doubles down on its decision to only cover a new class of Alzheimer’s drugs with participation in a registry—an announcement that continues to create a barrier for patients and undermines the FDA’s accelerated approval process. (551 words, 2 minutes, 45 seconds)
Read More

40% fewer drugs
Share
Good Day BIO Newsletter  •  June 1, 2023
A new study highlights the devastating impact of the Inflation Reduction Act’s drug price controls—plus, the FDA approved the second-ever RSV vaccine, bringing the total to two in one month. (480 words, 2 minutes, 24 seconds)
Read More

House passes bills to support startups
Share
Good Day BIO Newsletter  •  May 31, 2023
The House passed two bills—that BIO supports—that would help biotech startups. Plus, a recent poll finds likely voters want Medicare to cover FDA-approved Alzheimer’s treatments. (606 words, 3 minutes, 1 second)
Read More

Letter in support of U.S. Codex Office funding
Share
Letters, Testimony & Comments  •  May 30, 2023
BIO joined with more than 40 groups in calling on Congress to set 2024 funding for the U.S. Codex Office at or above the 2023 level. 
Read More

FDA approves new antibiotic but...
Share
Good Day BIO Newsletter  •  May 30, 2023
Back to work—including on Capitol Hill, where lawmakers have reportedly reached a deal on the debt ceiling. In the meantime, we look at a new antibiotic approved last week and what BIO’s saying about the U.S. Codex Office. (530 words, 2 minutes, 39 seconds)
Read More

BIO Comments to FDA (Docket No. FDA-2023-N-0398) on Methods and Approaches for Capturing Post-Approval Safety and Efficacy Data on Cell and Gene Therapy Products
Share
Letters, Testimony & Comments  •  May 26, 2023
In these comments, BIO addresses FDA’s four specific topic areas of consideration as the agency develops its draft guidance per PDUFA VII.
Read More

EPA's 'inexplicable' rule on PIPs
Share
Good Day BIO Newsletter  •  May 26, 2023
Before you head out for the holiday weekend, we have news on the EPA’s final rule on Plant Incorporated Protectants—plus, weekend reading. We’ll be back on Tuesday, May 30. Enjoy the weekend! (542 words, 2 minutes, 42 seconds)
Read More

BIO Comments to the FDA on Clinical Trial Considerations to Support Accelerated Approval of Oncology Therapeutics (Docket No. FDA–2023-D-0110)
Share
Letters, Testimony & Comments  •  May 25, 2023
BIO’s comments support accelerated approval as an important regulatory pathway that allows patients with serious and life-threatening illnesses such as cancer to have earlier access to promising therapies.
Read More

BIO Statement on PIPs Rule: EPA Misses Opportunity to Advance Food, Ag Innovation
Share
Press Release  •  May 25, 2023
The following statement concerning the Environmental Protection Agency’s final rule on regulation of Plant Incorporated Protectants (PIPs) under the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA) may be attributed to John Murphy, chief policy officer and deputy general counsel for the Biotechnology Innovation Organization (BIO). “EPA’s revisions to the PIPs regulations come at a critical time for technology developers and society as we innovate to meet global challenges including strengthening food security and climate adaptation, mitigation and resilience. EPA had an opportunity to streamline regulations of pesticidal substances in plants and expand exemptions that help bring new, innovative products made with precise gene editing tools to market. The revisions could have helped biotechnology harness the power of science to advance the bioeconomy and feed the world more securely and sustainably, goals that President Biden has declared in his Executive Order on biotechnology and innovation.   “Unfortunately, the agency’s final rule is a hugely missed opportunity. EPA’s rule inexplicably holds PIPs produced via biotechnology to a different standard than the same substances produced via plant breeding. This approach of holding the same or similar products to different standards merely due to their production method is not supported by science. EPA is imposing an extremely narrow exemption and burdensome data requirements that render this an exemption in name only.”
Read More

Pagination

  • First First page
  • Prev Previous page
  • …
  • 98
  • 99
  • 100
  • …
  • Next Next page
  • Last Last page
Biotechnology Innovation Organization
Explore BIO
Policy
Events
About
Industry Insights
Join Now
BIO PAC
For Members
Member Directory
BIO Policy Committees
Cost-Savings Program
BIO Events
BIO International Convention
BIO Partnering at JPM Week
BIO CEO & Investor Conference
BIO Investor Forum
BIO Patient Health & Advocacy Summit
BIO Intellectual Property Counsels Committee Conference
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2025 All Rights Reserved
Privacy Policy
Terms of Use
Contact BIO